Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.82 USD
Change Today +0.02 / 0.71%
Volume 854.4K
SQNM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Key Developments

Sequenom, Inc. Elects Catherine J. Mackey as New Member of its Board of Directors

Sequenom Inc. announced that its shareholders elected Catherine J. Mackey, Ph.D., as a new member of its Board of Directors, effective June 17, 2015. Dr. Mackey has also been appointed to the Audit and Nominating and Corporate Governance committees of the company's Board of Directors. Dr. Mackey is currently the Chief Executive Officer of CYPrus Therapeutics Inc.

Sequenom Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:30 PM

Sequenom Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: William J. Welch, Chief Executive Officer, President and Director.

Sequenom Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Sequenom Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $37.8 million, an increase of 2% compared to $37.1 million for the first quarter of 2014. Net earnings improved to $14.3 million, or $0.11 per diluted share as compared to a net loss of $15.7 million, or $0.13 per share, basic and diluted, for the first quarter of 2014. The improvement in the net earnings from the prior year is due to a $21.0 million gain on the pooled patents agreement with Illumina Inc., as well as improved gross margins and reduced operating expenses compared to the prior year first quarter. Operating income was $16.5 million as compared to operating loss of $14.4 million for the same period in 2014. Net cash used in operating activities was $7.2 million an improvement compared to $16.1 million for the first quarter of 2014. Earnings from continuing operations before income taxes were $14,360,000 against loss from continuing operations before income taxes of $16,545,000 a year ago. Purchases of property, equipment and leasehold improvements were $289,000 against $405,000 a year ago.

Sequenom Inc. Proposes Amendment to its Restated Certificate of Incorporation

Sequenom Inc. announced that the annual general meeting to be held on June 17, 2015, it has proposed an amendment to the company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 185,000,000 to 275,000,000 shares.

Sequenom Inc., Annual General Meeting, Jun 17, 2015

Sequenom Inc., Annual General Meeting, Jun 17, 2015., at 09:00 Pacific Standard Time. Location: 3595 John Hopkins Court. Agenda: To elect Kenneth F. Buechler, Myla Lai-Goldman, Richard A. Lerner, Ronald M. Lindsay, Catherine J. Mackey, David Pendarvis, Charles P. Slacik, Dirk van den Boom and William J. Welch as directors to hold office until the annual meeting of stockholders in 2016; to approve an amendment to the company’s restated certificate of incorporation to increase the number of authorized shares of common stock from 185,000,000 to 275,000,000 shares; to approve the compensation of the company’s named executive officers; to ratify audit committee’s selection of Ernst & Young LLP to be independent registered public accounting firm for the fiscal year ending December 31, 2015; and to conduct any other business properly brought before the meeting or any adjournment or postponement thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $2.82 USD +0.02

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biotage AB kr18.70 SEK -0.30
Enzo Biochem Inc $3.00 USD -0.02
Foundation Medicine Inc $20.30 USD -2.00
NanoString Technologies Inc $15.31 USD +0.13
Pacific Biosciences of California Inc $5.69 USD +0.15
View Industry Companies
 

Industry Analysis

SQNM

Industry Average

Valuation SQNM Industry Range
Price/Earnings 21.6x
Price/Sales 2.2x
Price/Book NM Not Meaningful
Price/Cash Flow 10.8x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.